Test Price
2,800 AED✅ Home Collection Available
DPM2 Gene Analysis – Glycosylation Disorder Type 1U – Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity
ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139) with NGS full-gene coverage and clinical-grade variant interpretation.
VIP Mobile Phlebotomy & Cold-Chain Home Collection
Temperature-controlled home collection across all seven emirates, 8 AM – 11 PM daily, with ISO-certified cold-chain transport for DNA integrity.
Post-Test Clinical Guidance
Telephonic result interpretation session with a qualified clinical genetic counsellor, aligned with DHA genetic testing protocols.
Direct Insurance Billing Verification
WhatsApp your Emirates ID and insurance card to +971 54 548 8731 for instant eligibility confirmation.
Test Overview & Methodology
The DPM2 Gene Genetic Test is a definitive molecular diagnostic tool that analyses the DPM2 gene for pathogenic variants associated with Congenital Disorder of Glycosylation Type 1U (CDG-1U), a rare autosomal recessive metabolic condition affecting dolichol-phosphate-mannose synthesis. This test utilises Next Generation Sequencing (NGS) to deliver comprehensive gene coverage, enabling precise identification of single nucleotide variants, small insertions, deletions, and copy number variations. The analysis confirms the genetic diagnosis and guides clinical management, surveillance, and family planning decisions.
| Feature | Our Test: DPM2 NGS Full Gene Analysis | Closest Alternative: Biochemical CDG Screening |
|---|---|---|
| Methodology | Next Generation Sequencing (NGS) – Full Gene Coverage | Transferrin Isoelectric Focusing (IEF) / Serum Glycan Profiling |
| Diagnostic Sensitivity | 99.9% for DPM2-CDG (Type 1U) | ~85% (non-definitive; cannot distinguish CDG subtypes) |
| Turnaround Time | 3 to 4 Weeks | 1 to 2 Weeks (screening only; requires confirmatory genetic test) |
| Clinical Actionability | Definitive molecular diagnosis; informs family planning and targeted management | Abnormal results require reflex to genetic testing for subtype confirmation |
| Sample Requirements | Whole Blood, Extracted DNA, or One Drop Blood on FTA Card | Serum (venipuncture required; fasting preferred) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) states: "The DPM2 NGS test is a critical diagnostic tool for families navigating unexplained developmental delay, hypotonia, or multisystem involvement suggestive of congenital disorders of glycosylation. I urge all patients and families to interpret results exclusively through a qualified clinical geneticist or metabolic specialist, as variant significance must be correlated with the full clinical phenotype. No single genetic result should dictate clinical decisions in isolation."
Medication Advisory
Maintain all prescribed therapies unless explicitly directed otherwise by your supervising physician. Genetic test outcomes offer diagnostic clarity but are not a substitute for ongoing clinical monitoring and medical management.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria – Do Not Proceed Without Resolution
- Inability to provide informed consent (patient or legal guardian, per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability for minors)
- Inadequate or contaminated DNA sample (repeat collection will be advised)
- Refusal or unavailability for mandatory pre-test genetic counselling session
- Active severe psychiatric instability contraindicating disclosure of genetic results
Emergency Red Flags – Seek Immediate Medical Attention
- Acute psychological distress, suicidal ideation, or severe anxiety following result disclosure
- New-onset seizures or neurological deterioration in a patient awaiting or following test results
- Signs of metabolic decompensation: vomiting, lethargy, hypoglycaemia, or altered consciousness
Patient FAQ & Clinical Guidance
1. What is the DPM2 Gene Glycosylation Disorder Type 1U Genetic Test and why is it ordered?
The DPM2 Gene NGS Test detects pathogenic mutations in the DPM2 gene causing Congenital Disorder of Glycosylation Type 1U with 99.9% diagnostic sensitivity. This test is typically ordered when a patient presents with unexplained developmental delay, hypotonia, seizures, coagulopathy, or multisystem involvement suggestive of a congenital disorder of glycosylation. It provides a definitive molecular diagnosis that can guide clinical management, inform prognosis, and enable accurate genetic counselling for family planning.
2. How is the DPM2 NGS test performed and what are the sample requirements?
The test requires a whole blood sample, extracted DNA, or a single drop of blood on an FTA card, collected by a DHA-licensed phlebotomist during a home or clinic visit. DNA is extracted and sequenced using NGS technology that covers all coding exons and splice junctions of the DPM2 gene. A mandatory pre-test genetic counselling session is required to obtain informed consent, draw a detailed pedigree chart, and document the clinical history of affected family members. Results are delivered within 3 to 4 weeks.
3. Is home collection available across the UAE and how do I verify my insurance coverage?
Yes, ISO-certified hospital-grade home collection is available across all seven emirates from 8 AM to 11 PM daily, with cold-chain transport ensuring complete DNA sample integrity. To verify your insurance coverage, simply send your Emirates ID and insurance card via WhatsApp to +971 54 548 8731 for immediate direct billing confirmation. Our team will respond within minutes during operational hours and provide a clear breakdown of covered versus out-of-pocket costs before your appointment is confirmed.
UAE Regulatory & Data Privacy Adherence
All genetic testing and data processing are conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, clinical safety, and medical liability adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All genomic data are encrypted and stored on UAE-sovereign servers. Laboratory accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | DPM2 Gene Analysis – Congenital Disorder of Glycosylation Type 1U (CDG-1U) – NGS Full Gene Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | E77.8, E77.9, Z13.228 |
| LOINC Code | 101387-9 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians